CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

Ruchi Gupta, Khaliqur Rahman, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand
  • Ruchi Gupta
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India | ruchipgi@yahoo.co.in
  • Khaliqur Rahman
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India
  • Khaliqur Rahman
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India
  • Manish Kumar Singh
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India
  • Surabhi Kumari
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India
  • Geeta yadav
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India
  • Soniya Nityanand
    Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, India

Abstract

Background: Myelodysplastic syndrome (MDS) is a heterogeneous disorder characterized clinically by presence of cytopenia/s. Limited data is available pertaining to the morphological spectrum and cytogenetic profile of Indian MDS patients. The aim of the study was to ascertain the clinco pathological, morphological and cytogenetic spectrum of Indian MDS patients. 

Material and methods: A retrospective analysis of all patients diagnosed as MDS from June 2012-December 2016 was performed. Their clinical and laboratory data was collated and reviewed.

Results: A total of 150 patients of as primary MDS were evaluated with M: F ratio of 1.6:1 and median age of 55.5 years. 64% patients presented with pancytopenia, with thrombocytopenia alone was seen in only 2 cases. There were 66 (44%) cases of MDS-MLD, 33 (22%) MDS-EB 2, 32 (21.3%) MDS–EB 1, 13 (8.6%) cases MDS-SLD and two cases each of MDS-SLD-RS, MDS-MLD-RS and RCC. Cytogenetic data was available in 86/150 patients, 50% of which were abnormal. Complex karyotype was observed to be the commonest abnormality (27.5%). Novel translocations like t(9;22)(q11.2;q34.2) in addition to other abnormalities (n=3), t(2;4)(p25;q23),t(1;5)(p22;q33), t(1;12)(p34;p11.2) and t(5;7;9;)(q13;q32;p22) were observed.

Conclusion: The median age of patients in India is almost a decade younger than the western population. Moreover, majority of the patients belonged to the high risk IPSS-R prognostic group (31.4%), followed by intermediate (29%) and very high risk groups (24.4%) in our cohort of patients. Seventy percent individuals, < 40 years belonged to the high prognostic categories, indicating that Indian MDS patients have high disease burden and in turn more likelihood for leukemic transformation.

Keywords

MDS, cytogenetics, India

Full Text:

PDF
HTML
Submitted: 2017-04-22 17:25:07
Published: 2017-08-16 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar

References

References

Swerdlow S CE, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon.

Hasse D. Cytogenetic features in myelodysplastic syndromes. Annals of Hematology 87:515-26. DOI: 10.1007/s00277-008-0483-y PMID: 18414863 PMCID: PMC2413090

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65. DOI: 10.1182/blood-2012-03-420489 PMID: 22740453 PMCID: PMC4425443

Varma N, Varma S. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol Microbiol. 2008 Jan-Mar;51(1):97-101. PMID: 18417875

Vundinti BR, Kerketta L, Jijina F, Ghosh K. Cytogenetic study of myelodysplastic syndrome from India. Indian J Med Res. 2009 Aug;130(2):155-9. PMID: 19797812

Shah NM, Prajapati SG, Adesara RP, Patel AP. An analysis of 30 cases of myelodysplastic syndrome. Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):206-9. PMID: 19332914

Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res. 2011 Oct;134:452-7. PMID: 22089606 PMCID: PMC3237242

Rajendran R, CN Sai, Suman D, Krishnarathnam K, Rajendran R, Koshy T et al. Profile of myelodysplastic syndrome: A study done at tertiary care centre from south India. International Journal of Recent Trends in Science and Technology 2015;15:606-09.

Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma. 2007 Jul;48(7):1372-8. DOI: 10.1080/10428190701377063 PMID: 17613766

Geddes AA, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Haematol. 1990 Oct;76(2):194-202. PMID: 2094322

Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 2007 May;137(3):193-205. DOI: 10.1111/j.1365-2141.2007.06537.x PMID: 17408458

Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia- retrospective study and review of literature. Leuk Res. 2004 Jun;28(6):579-86. DOI: 10.1016/j.leukres.2003.10.027 PMID: 15120934

Abstract views:
226

Views:
PDF
74
HTML
104

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2017 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185